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Abstract The B-cell activator factor (BAFF)/BAFF receptor
(BAFF-R) axis seems to play an important role in the develop-
ment and progression of chronic lymphocytic leukemia (CLL).
Here, we investigated the association of eight single nucleotide
polymorphisms (SNPs) in the BAFF (TNFSF13B) and BAFF-
R (TNFRSF13C) genes with risk of sporadic CLL in a group of
439 CLL patients and 477 controls. We also examined the
correlation between selected SNPs andCLL clinical parameters
as well as BAFF plasma levels and intracellular BAFF expres-
sion. Our results point to a possible association between the
rs9514828 (CT vs. CC + TT; OR = 0.74; CI 95 % = 0.57;
0.97; p = 0.022) and rs1041569 (AT vs. AA + TT;
OR = 0.72; CI 95 % = 0.54; 0.95; p = 0.021) of BAFF gene
and rs61756766 (CC vs. CT; OR = 2.03; CI 95 % = 1.03; 3.99;
p = 0.03) of BAFF-R gene and CLL risk. Additionally, we
observed that homozygotes rs1041569 AA and TT had a
slightly higher risk (HR = 1.12) for the need of treatment in
comparison to AT heterozygotes. In conclusion, our results
indicate that SNPs in BAFF and BAFF-R genes may be con-
sidered as potential CLL risk factors.
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Introduction
Chronic lymphocytic leukemia (CLL) is one of the most preva-
lent leukemias in Western countries [1] with an incidence of 4.1
per 100,000 persons per year [2]. The characteristic feature of
this disease is the gradual accumulation of mature B cells pre-
senting typical markers such as CD5, CD19, CD20, and CD23
in lymphoid tissues, bone marrow, and peripheral blood (PB)
[1, 3]. The CLL cell accumulation is caused by the disruption of
programmed cell death rather than acute proliferation [1, 3].
B-cell activator factor (BAFF) (other names: BLys,
TNFSF13B) and some other members of the tumor necrosis
factor (TNF) family proteins have been shown to be engaged in
providing survival signals to B cells by affecting genes associ-
ated with apoptosis [3]. BAFF binds to the following receptors:
B cell maturation antigen (BCMA; TNFRSF17), transmem-
brane activator and calcium-modulator and cyclophilin ligand
interactor (TACI; TNFRSF13B), and BAFF receptor (BAFF-
R; TNFRSF13C) [4] which is a specific receptor for BAFF [5]
and plays a key role in its biology [6].
BAFF-R is mainly expressed on B cells [6], and its expres-
sion on various B cell lines strongly correlates with BAFF
binding to these cell lines [5]. Moreover, BAFF/BAFF-R sig-
naling plays a central role in the survival and growth of normal
and neoplastic B lymphocytes [5]. The aberrant expression of
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BAFF and BAFF-R has been reported, among others, in non-
Hodgkin lymphomas (NHLs) including CLL [3, 5]. The SNP
array designed to screen, inter alia, genes from TNF and TNF
receptor superfamilies, as well as NFκB and related transcrip-
tion factors, delineated BAFF (TNFSF13B) and BAFF-R
(TNFRSF13C) genes as associated with NHL risk.
Moreover, analysis conducted by NHL subtype revealed
BAFF (TNFSF13B) to be associated specifically with CLL/
small lymphocytic lymphoma (SLL) [7].
On the basis of these data, the hypothesis that the BAFF/
BAFF-R pathway may play a role in the development and
pathogenesis of this disease has been put forward [5].
The following observations support this hypothesis.
Aberrant serum soluble BAFF levels have been reported in
NHL patients including CLL patients [5, 8–11]. Correlations
between BAFF expression and some clinical prognosis
markers have been reported [5], and, what is more, the use of
BAFF serum levels together with CD38, ZAP70 expression,
and immunoglobulin heavy chain variable (IGHV) mutational
status has been presented as a promising marker in CLL [12].
Genetic evidence also supports the above-mentioned hy-
pothesis. Polymorphism rs9514828 (−871 C>T) in the pro-
moter region of the BAFF gene has been associated with high
levels of serum BAFF and familial CLL [3] and NHL risk
[13]. A new mutation in the BAFF-R gene rs61756766
(His159Tyr) was determined in tumor and germline tissues
from a subset of NHL patients [5, 6]. Additionally, the results
of our preliminary study pointed to a possible association
between genetic variations of BAFF and BAFF-R genes and
the risk of sporadic CLL [14].
Since the BAFF/BAFF-R axis seems to play an important
role in the development and progression of CLL, we decided
to extend our previous study to investigate the association
between single nucleotide polymorphisms (SNPs) of the
BAFF and BAFF-R genes and CLL risk. We also examined
the correlation between these SNPs and CLL clinical param-




Patient population (N = 439) was composed of two cohorts of
CLL patients. The majority of the first group (193 CLL pa-
tients; 85 females and 108 males) had entered into our previ-
ous study [14]. These patients were diagnosed with CLL in the
Department of Hematology, Neoplastic Disease, and Bone
Marrow Transplantation of Medical University of Wroclaw.
The second group consisted of 246 patients (107 females and
139 males) diagnosed in the Department of Hematooncology
and Bone Marrow Transplantation of Medical University of
Lublin. Table 1 contains characteristics of CLL patients.
Diagnosis of CLL was based on criteria from the
International Workshop on Chronic Lymphocytic Leukemia
(IWCLL) [15]. The follow-up period of this group was from 2
to 171 months (means ± SD = 58.01 ± 33.99). During this
period, 106 patient indications for cytostatic treatment accord-
ing to the IWCLL [15] were established. The period from the
enrolment into the study and treatment ranged from 0.5 to
123 months (mean ± SD = 14.14 ± 21.75).
The control population was composed of 477 (296 subjects
from our previous study and 181 additional subjects) random-
ly selected blood donors of Polish Caucasian origin (243 fe-
males and 234 males).
This study was approved by the Ethics Committee of the
Medical University of Wroclaw and the Ethics Committee of
the Medical University of Lublin. Written informed consent
was obtained from all participants.
Selection of single nucleotide polymorphisms
SNPs, as previously described [14], were selected based on
available literature [6, 16] and in silico analysis [17, 18].
The following SNPs of the 5′-untranslated region (UTR) of
BAFF (TNFSF13B; 13q33.3) were examined: rs9514827
T>C (−2841); rs3759467 T>C (−2704); rs1041569 A>T
(−2701); and rs9514828 C>T (−871) [14, 16]. According to
in silico analysis, all these SNPs are located in the potential
transcription factors binding sites (TFBS) [14, 17, 18].
As previously [14], we investigated four SNPs of BAFF-R
(TNFRSF13C; 22q13.2): rs5996088 G>A (5′-near gene; po-
tential TFB site); rs61756766 C>T (His159Tyr) [6] (Online
Resource—Supplementary Fig. 1); rs7290134 T>C (3′-UTR;
the potential miRNA binding site), and rs6002551 C>T (de-
scribed by Wang et al. as a polymorphic variant of BAFF-R
associated with NHL (7).
DNA isolation and genotyping
Genomic DNAwas isolated from whole blood using Invisorb
Blood Midi Kit (Stratec Molecular GmbH, Berlin, Germany)
according to the manufacturer’s protocol. The following SNPs
were genotyped by restriction fragment length polymorphism
(RFLP): BAFF (rs1041569; rs9514827) [14, 16] and BAFF-R
(rs61756766; rs6002551) [6, 14]. Primer sequences, annealing
temperatures, and restriction enzymes are listed in Online
Resource (Supplementary Table 1). Polymerase chain reactions
(PCRs) were run on T100™ Thermal Cycler (Bio-Rad,
Hercules, CA, USA). Allelic discrimination method with
application of TaqMan SNP Genotyping Assays (Thermo
Fisher Scientific, Waltham, MA, USA) was used to determine
the following SNPs: BAFF (rs3759467, assay ID
C_27497010_10) and BAFF-R (rs7290134, assay ID
C_2189968_1_; rs5996088, assay ID C_30413471_10) [14].
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The reactions were run onApplied Biosystems 7300 Real-Time
PCR System (Thermo Fisher Scientific, Waltham, MA, USA
(Online Resource—Supplementary Table 2 contains a detailed
list of assays used in this study). The BAFF rs9514828 was
examined by both RFLP [16] (AciI, catalog no. R0551, New
England Biolabs® Inc., Ipswich, MA, USA) and TaqMan
methods (assay ID C_29641742_10) or by double genotyping
with a TaqMan probe. Accuracy of genotyping methods for all
SNPs was verified by direct sequencing of a few samples
representing homozygotes of two types and heterozygotes for
each investigated SNP. These samples were used as reference
samples in the following genotyping experiments.
Intracellular analysis of BAFF
Peripheral blood samples from CLL patients were stained for
intracellular BAFF expression as previously described [8].
Briefly, analysis of intracellular BAFF expression by CD19+
cells was performed on fresh PB samples. Monoclonal antibod-
ies (MoAbs) used for analyses included anti-CD19 PE (Clone
HIB 19, IgG1, BD Pharmingen, San Diego, CA, USA) and
fluorescein isothiocyanate (FITC)-conjugated anti-BAFF
(Clone 137314, IgG1, R&D Systems, Minneapolis, MN
USA). The samples were analyzed by flow cytometry directly
after preparation. For data acquisition and analysis, a
FACSCalibur instrument with CellQuest software (Becton
Dickinson, Franklin Lakes, NJ, USA) was used. The percent-
age of positive cells was measured from a cutoff set using an
isotype-matched nonspecific control antibody.
Analysis of ZAP-70 expression in CLL cells
CLL cells were stained for ZAP-70 protein expression as
previously described [8]. Briefly, ZAP-70-positive cells were
evaluated in the PB via analysis of the surface expression of
CD19 and CD5 antigens, as well as intracellular expression of
ZAP-70 by flow cytometry. The percentage of CD19+CD5+
ZAP-70+ cells was determined. MoAbs used for analyses
included anti-ZAP-70 PE (Clone 1E7.2, IgG1, BD
Biosciences, Franklin Lakes, NJ, USA) and anti-CD19 FITC
(Clone HIB19, IgG1) and anti-CD5 PE-Cy5 (Clone UCHT2,
IgG1) (BD Pharmingen, San Diego, CA, USA). The cutoff
point for ZAP-70 positivity in leukemic cells was ≥20 %.
Detection of CD38 expression
As previously described [8], flow cytometry analysis of CD38
was performed on fresh PB samples stained with anti-CD38
FITC (Clone HIT2, IgG1), anti-CD5 PE-Cy5, and anti-CD19
PE (BD Pharmingen, San Diego, CA, USA). A standard,
whole-blood assay with erythrocyte cell lysis was used for
preparing the PB specimens. The samples were analyzed by
flow cytometry directly after preparation. CLL cells were con-
sidered CD38-positive when ≥20 % was expressed in the
membrane antigen.
Plasma BAFF immunoassay
As previously described [8], a commercial enzyme-linked
immunosorbent assay (ELISA) kit, Quantikine Human
BAFF/BLyS Immunoassay (R&D Systems , Inc .
Minneapolis, MN, USA), was used for quantitative determi-
nation of human BAFF in plasma samples. We followed the
protocol recommended by the manufacturer. The ELISA
Reader Elx800 (BioTek Instruments, Winooski, VT, USA)
was used [8].
Statistical analysis
As in our preliminary study [14], chi-square test,χ2df, was used
to test the null hypothesis that cases and controls have the same
distribution of genotype counts. To control type I error in the
case of many tests for differences between SNP genotypes of
cases and controls, a global (omnibus) chi-square test was per-
formed, first to test the hypothesis zero, H0, which states that
there were no differences between cases and controls in any
Table 1 Characteristics of CLL patient group
Variables Min Q1 Median Sn Q3 Max
Age at diagnosis 31 55.5 64 10 71 91
WBC 3.25 18.4 30.36 18.38 56.02 387.2
LIMF 2.12 12.48 22.24 14.99 46.4 232
HGB 7.04 12.1 13.4 1.3 14.4 18.1
PLT 17 133 178 50 214 626
B2M 0.56 2.135 2.735 0.94 3.828 12.79
LDH 1 39.25 72 40 107.8 163
Variables Yes No Σ % Yes CI 95 %
Woman 192 247 439 43.7 39 48.5
Therapy 106 140 246 43.1 36.8 49.5
ZAP70a 88 158 246 35.8 29.8 42.1
CD38a 81 165 246 32.9 27.1 39.2
CD5a 239 7 246 97.2 94.2 98.8
Rai 0 I II III IV Σ
N 135 111 100 26 67 439
% 30.8 25.3 22.8 5.9 15.3 100 %
cum. % 30.8 56.1 78.9 84.8 100 % –
Not all clinical data were available for all of the patients
Q1 1st quartile,Q3 3rd quartile, Sn variability measure,WBCwhile blood
cell (G/L), LIMF lymphocyte count (G/L), HGB hemoglobin (g/dl), PLT
platelets (G/L), LDH lactate dehydrogenase (IU/L), B2M β2-
microglobulin (mg/dl), Rai Rai stage
a Cutoff (20 %)
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SNP, opposite to the alternative, H1, which states that genotype
frequencies in cases and controls were different at least in one
SNP. Due to correlation between SNP distributions (linkage
disequilibrium present), the distribution of global chi-square
statistic was estimated numerically. In the case of small num-
bers, test statistics distribution was estimated numerically.Odds
ratio (OR) was computed as the measure of effect size. Median
was used as the location parameter. In the case of the median,
the Snstatistic was computed as the measure of variability: Sn =
med{med|xi − xj|; j = 1 ... n} [19]. Sn is the typical distance be-
tween two randomly selected individuals and is used as the
measure of variability instead of standard deviations when me-
dian is used instead of arithmetic mean. Additionally, the 1st
and 3rd quartiles and minimal and maximal observations were
reported. A linear model was used to test relations between
SNP haplotypes and time to treatment (TTT) and requirement
for introducing treatment. The likelihood ratio statistic,
LRS ∼ χ2, was used to test regression coefficients. The differ-
ence between two medians of plasma BAFF level was tested
based on the bootstrapped studentized T statistic. Deviation
from the Hardy-Weinberg equilibrium (HWE) was estimated
with the chi-square test andmeasured as f ¼ pCC−p2CpC 1−pCð Þ, where pC
and pCC are allele C and genotype CC frequencies while f < 0
and f > 0 correspond to deficiency and excess of homozygotes,
respectively, and f = 0 in the case of HWE. Haplotype frequen-
cies (HFs) among SNPs were estimated with the maximum
likelihood function [20]. Differences in genotype distributions
between two groups of cases and between combined group of
cases and controls were tested with the χ2 statistic, and the
distribution of χ2 was estimated numerically. Analysis was
performed using GNU Octave software version 3.8.2.
Results
The case-control study was carried out on groups of patients
and controls described in the BStudy population^ section.
There was no evidence that two groups of patients were dif-
ferent in terms of genotype distribution for any of the exam-
ined SNPs (χ2df≈39 = 43.97, p = 0.2673), so it allowed us to
combine patients groups (193 + 246) in order to increase the
statistical power of the present case-control study. The global
(omnibus) test for homogeneity (χ2 = 55 on approximately 35
degrees of freedom, ratio χ2/df = 1.57) showed that the CLL
group differed from the healthy control (HC) group in at least
one SNP (χ2df=35 = 55; p = 0.026).
Hardy-Weinberg equilibrium
Seven out of eight SNPs investigated in this study were in the
Hardy-Weinberg equilibrium in HC (Table 2 and Online
Resource—Supplementary Table 3). The genotype distribution
for rs9514828 differed from that expected under HWE in HC
(p = 0.015; f = −0.116; CI 95 % = −0.21, −0.03). We did not
exclude this variant from the analysis for several reasons. This
particular SNP is functional and was the only one out of 20
SNPs examined (this manuscript presents only results for
BAFF and BAFF-R) in our HC group for which deviation from
HWE (DHW) was observed. It is well established that the most
common sources of deviation fromHWE are genotyping errors
or population stratification [21]. Genotyping errors were ex-
cluded by double genotyping and by the fact that the patient
group was in HWE. It is also hardly likely that our study pop-
ulation was stratified resulting from the admixture of other
ethnic groups since both of the investigated groups are of
Polish origin and they did not differ in terms of allele frequency.
The C and T alleles frequencies were as follows: HC patients,
C—56.9 %, T—43.1 %; and CLL patients, C—56.8 %, T—
43.2 %.
From the statistical point of view, it is not surprising that
one out of 20 SNPs tested at α = 0.05 was not in HWE, and as
a matter of fact it is expected, even if all 20 examined SNPs in
the general population were in HWE. Let s be the number of
examined SNPs which are not in HWE in the sample at α =
0.05 and let r be the number of examined SNPs which are in
HWE in the general population. We then get P(s ≥ 1| r =
20,α = 0.05) = 0.6415.
BAFF and BAFF-R polymorphisms and risk of CLL
In our preliminary study, we observed a difference in genotype
distribution between the CLL patients and the controls for the
rs9514828 BAFF variant (χ2df=1 = 3.946; p = 0.047) [14].
Here, in larger groups, we confirmed this difference
(χ2df=1 = 5.23; p = 0.022) (Table 2). The risk of CLL for
rs9514828 CT heterozygotes was lower than that for homo-
zygotes CC (OR = 0.77; CI 95 % = 0.57, 1.03), while for
rs9514828 TT homozygotes this risk was almost the same as
for rs9514828 CC homozygotes (OR = 1.11 CI 95 % = 0.75,
1.63). Therefore, according to the parsimony rule, we as-
sumed the overdominant model. The conducted analysis con-
firmed our assumption. In this model, heterozygotes had a
protective effect (CT vs. CC + TT; χ2df=1 = 5.229;
OR = 0.74; CI 95 % = 0.57, 0.97; p = 0.022).
In addition, we observed a difference in genotype distribu-
tion between the CLL patients and the controls for rs1041569
(χ2df=1 = 5.29; p = 0.02). Similarly, the genotype rs1041569
AT was protective when compared to rs1041569 AA
(OR = 0.74; CI 95 % = 0.56, 0.99) (Table 2). The overdom-
inant model applied in this case showed protective effect of
heterozygote AT (AT vs. AA + TT; χ2df=1 = 5.886; OR = 0.72;
CI 95 % = 0.54, 0.95; p = 0.021).
In our preliminary study [14], we observed a higher risk of
CLL for rs61756766 CT heterozygotes, a very rare variant of
the BAFF-R gene (OR = 1.79; CI 95 % = 0.73, 4.39), but the
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power of that study was low. Here, on larger groups, we noted
a significant difference in genotype distribution between pa-
tients and controls (χ2df=1 = 4.43; p = 0.03) (Table 2).
Moreover, we found the association between the rs61756766
CT genotype and the risk of CLL (OR = 2.03; CI 95% = 1.03,
3.99). As previously [14], we did not determine any TT ho-
mozygote in patients or in controls.
Supplementary Table 3 (Online Resource) shows the dis-
tribution of the BAFF rs9514827 and rs3759467 and BAFF-R
rs6002551, rs5996088, and rs7290134 gene polymorphisms
investigated in this study for which distribution of genotypes
was similar in patients and controls.
Additionally, we compared the distribution of BAFF and
BAFF-R haplotypes between patients and controls. We noted
a significant difference in haplotype distribution between HC
and CLL subjects for BAFF-R (χ2df=6 = 17.4; p = 0.008)
(Online Resource; Supplementary Table 4). There was no
gene × gene interaction between BAFF and BAFF-R associ-
ated with the risk of CLL.
Plasma BAFF, intracellular expression of BAFF,
and polymorphisms of BAFF
We investigated the possible association between all BAFF
SNPs analyzed in this study as well as the (1) plasma BAFF
level and the (2) intracellular expression of BAFF protein in
PB CD19+ cells. We failed to find any of the BAFF SNPs
examined in this study to be associated with plasma BAFF
level (Fdf=8155 = 1.154, p = 0.331) (Online Resource;
Supplementary Table 5) or to be associated with intracellular
expression of BAFF in PB CD19+ cells (Fdf=8112 = 1.166,
p = 0.326) (Online Resource; Supplementary Table 6).
BAFF and BAFF-R polymorphisms and clinical
parameters
Since CD38 and ZAP70 are important prognostic markers of
CLL, we divided patients into the following groups (using a
20 % cutoff value for CD38 and ZAP70): CD38+ and CD38−,
and ZAP70+ and ZAP70−. Next, we compared the genotype
distribution of all investigated SNPs of BAFF and BAFF-R
between CD38+ and CD38− and ZAP70+ and ZAP70− CLL
patients, but we did not find any significant differences. Also,
none of the examined SNPs was associated with Rai stage.
Next, we analyzed correlations between the appearance of
cytostatic treatment indications and time to treatment during
the follow-up period of 2 to 171 months as well as the (1)
haplotypes of BAFF and (2) rs1041569 and (3) rs9514828
of BAFF. There was no association between the requirement
of the treatment and haplotypes (χ2df=8 = 4.38; p = 0.82)
(Online Resource; Supplementary Table 7) as well as between
treatment requirement and individual SNPs (rs1041569
χ2df=1 = 0.77; p = 0.68; rs9514828 χ
2
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Similarly, we did not observe a relationship between TTT and
haplotypes of BAFF (Online Resource; Supplementary
Table 8) (χ2df=6 = 5.97; p = 0.43).
Since we noticed that heterozygotes rs9514828 CT and
rs1041569 AT had lower risk of CLL, in the next stage we
analyzed TTT in relation to heterozygosity at rs1041569 and
rs9514828 loci of the BAFF gene (Table 3). We noted that the
average TTT for the rs1041569 AT heterozygotes was longer
than in the group of AA and TT homozygotes. Homozygotes
had 1.12 (HR = 1.12) times higher risk for the need of treat-
ment (p = 0.316; CI 95 % = 0.7, 1.79). This result is encour-
aging because in practice it means that the TTT for patients
carrying the AT genotype is more than two times longer than
for patients carrying the AA or TT genotype (Fig. 1.) We also
checked whether the heterozygotes at rs9514828 and
rs1041569 would have longer overall survival (OS) in com-
parison to homozygotes, but we did not observe such a rela-
tion (p = 0.851 and p = 0.957, respectively).
Discussion
In our previous preliminary study, we investigated 20 SNPs of
the BAFF/APRIL system and their association with CLL risk
and some clinical parameters [14]. Here, we examined the
association of BAFF and BAFF-R polymorphisms and CLL
risk on a much larger group of patients (N = 439) and controls
(N = 477) to confirm our previous findings [14].
The BAFF gene rs9514828 is located within the binding
site of the myeloid zinc finger protein 1 (MZF1) transcription
factor (TF) [9], and its functionality has been shown in lucif-
erase assays, where the rs9514828 Tallele was associatedwith
higher luciferase activity [9, 22]. In contrast, however,
Almeida and Petzl-Erler [23] who investigated BAFF expres-
sion by unstimulated cells (CD8+ Tcells, monocytes, and NK
cells) isolated from healthy individuals at protein and mRNA
levels found that the rs9514828 CC genotype was associated
with significantly higher BAFF expression.
The association of rs9514828 with different diseases such
as primary Sjögren’s syndrome (pSS) [24], familial CLL [9],
idiopathic thrombocytopenic purpura [25], hepatitis C virus-
associated mixed cryoglobulinemia [26], pemphigus foliaceus
[27], and T-cell lymphomas [22] has been reported. Of note,
the protective or risk effect for C and Talleles has been shown
for different diseases [9, 14, 22–25, 27].
In our previous study, we observed the difference in
rs9514828 genotype distribution between CLL patients and
HC (p = 0.047) [14].
Due to the above-mentioned contradictory data regarding
the association of the rs9514828 variant with different dis-
eases and the association of the T and C alleles with aberrant
BAFF expression and our own data, we were prompted to
verify these observations on larger groups of healthy and
CLL subjects.
We confirmed our previous finding showing the difference
in genotype distribution between CLL patients and controls
for rs9514828. Based on obtained OR values, we assumed the
overdominant model in which heterozygotes had protective
effect.
As was mentioned earlier, rs9514828 is located within the
MZF1-binding site [9]. We ran an in silico analysis using
ConSite software [28] and found that the binding of MZF1
is predicted to be less strong for the C allele (score 8.510) than
for the T allele (score 9.085). MZF1 has been shown to be
involved in hematopoietic malignancies. MZF1 is a promoter/
enhancer binding-type transcription factor and has been
shown to act as a trans activator as well as a trans repressor,
and it has been suggested that its oncogenic activity may be
related to combined values of increased and decreased expres-
sion of target genes [29]. Moreover, ConSite software predict-
ed the presence of a potential binding site for Sp1 transcription
factor but only for the C allele (score 6.115). One of the mech-
anisms allowing neoplastic cells to survive and develop is the
ability to overcome the intrinsic and extrinsic signals which in
normal conditions lead to apoptosis. Sp1 transcription factor
has been shown to be involved in regulation of numerous pro-
and anti-apoptotic proteins such as BCL-2 or MCL1. It has
also been reported that Sp1 regulation may act in two opposite
directions. It may promote neoplastic cell resistance to apo-
ptosis but may also promote these cells’ sensitivity to induc-
tion of apoptosis [30].
Taking into consideration the results of the in silico analy-
sis, one may speculate that rs9514828 polymorphism may
influence the regulation of the BAFF gene by affecting the
binding sites of the above-mentioned transcription factors.
The normal and neoplastic cells may differ in terms of expres-
sion level of these transcription factors which may influence
the BAFF regulation.
Since both C and T alleles have been shown to have a
different effect of BAFF expression in neoplastic cells, cell
lines, and cells isolated from healthy donors and have been
found to be predisposing or protecting in different diseases, it
cannot be excluded that having both alleles may be advanta-
geous by allowing cells to adjust to normal and/or abnormal
Table 3 The time to treatment in relation to heterozygosity in
rs1041569 and rs9514828 loci of BAFF gene
SNP Genotyp N Min Q1 Median Sn Q3 Max
rs1041569 AA + TT 59 0 1 3 3 12 123
AT 26 0.5 2.3 9 8.5 22.3 48.5
rs9514828 CC + TT 59 0.5 1 4 3.8 11.5 48.5
CT 26 0 1 4 4.8 21.3 123
N number of patients,Min minimum, Q1 1st quartile, Q3 3rd quartile, Sn
variability measure, Max maximum
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conditions. Further research is required to test our hypothesis.
First of all, it has to be investigated if the predicted in silico
binding sites for transcription factors are functional.
Subsequently, it has to be checked if and how these TFs reg-
ulate BAFF. Also, the expression level of MZF1 and Sp1
factors should be compared between CLL and normal cells.
According to our best knowledge, apart from our stud-
ies (present and preliminary [14]) in the literature there is only
one other study investigating the association of BAFF gene
polymorphism rs9514828 with sporadic CLL [10]. Novak
et al. [10] did not find this variant to be associated with the risk
of NHL or CLL. However, that study involved only 123 CLL/
SLL cases [10]. Due to the discrepancy between this and our
study, the association of rs9514828 with the risk of CLL re-
mains to be examined in additional, independent studies. It
needs to be clarified, whether this SNP is a true risk variant of
CLL and if it is specific only for familial CLL [9] or both
sporadic and familial CLL.
Apart from the association between rs9514828 and CLL, we
also observed a significant difference in genotype distribution
between CLL patients and controls for rs1041569. In the over-
dominant model, the AT heterozygotes showed a protective ef-
fect. Faustova et al. [31] reported a significant association of the
rs1041569 T allele with myositis [31]. Nezos et al. [24] investi-
gated rs1041569 polymorphism in primary Sjögren’s syndrome,
but this group excluded this SNP from most of the conducted
analysis since it was not in HWE in the healthy control group
[24]. Recently, Lin et al. [32] have investigated rs1041569 in
autoimmune thyroid diseases (Grave’s disease and Hashimoto’s
thyroiditis). They did not find an association between this SNP
and the examined diseases, but OR and CI 95% reported by this
group for rs1041569 AT heterozygotes (OR = 0.79; CI 95 %
0.57, 1.10) [32] were similar to the figure observed by us
(OR = 0.74; CI 95 % = 0.57, 0.97). It is difficult to draw any
definite conclusion regarding the ORs for TT homozygotes
based on our and Lin et al.’s [32] studies due to the low frequen-
cy of this genotype observed in both populations as well as the
CI 95 % values (our study, 2.3 %; CI 95 % = 0.96, 4.13; Lin
et al.’s study [32], 1.1 %; CI 95 % = 0.14, 2.93).
The in silico analysis via application of ConSite [28] and
SNPinfo [17] showed that this variant is located within the
E47 (Thing1/E47) TFBS. The calculated matrix similarity
for E47 (Thing1/E47) at position rs1041569 suggests better
binding of this TF to the A allele (ConSite scores for A allele
9.982 and 8.897 for T allele; SNPinfo: A allele core similarity
1 and matrix similarity 0.928; T allele core similarity 1 and
matrix similarity 0.911).
E12 and E47 are products of the alternative splicing of a
single TCF3 (E2A) gene. They belong to the class I helix-loop
helix (bHLH) proteins and are broadly expressed, multifunc-
tional TFs playing a role in many developmental processes
[33, 34]. These two proteins can act both as tumor suppressors
and as tumor promoters [35]. E2A (E47) TF plays a key role in
B-cell development, maturation, and function and regulates
proliferation and survival of these cells [36].
It has been shown that E2A (E47) is overexpressed in CLL
cells. Elimination of this TF caused increased apoptosis [36].
Additionally, ConSite prediction showed that the T allele
caused the disappearance of the GATA-2 binding site (score
4.174 for A allele) and introduced the possible binding site for
PU.1 (SPI-1 score 4.776). However, due to limited informa-
tion available about the function of this SNP, it is difficult to
propose the mechanism which will explain the observed pro-
tective effect for AT heterozygotes. As was mentioned above,
the rs1041569 TT homozygotes are rare, and study on larger
sample size of CLL patients and healthy controls is needed to
verify the effect associated with this genotype and the risk of
CLL. Moreover, our study is the first (according to our best
Fig. 1 Kaplan-Meier estimates of
the time to treatment of CLL
patients in relation to rs1041569
genotypes
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knowledge) to report an association between rs1041569 and
the risk of CLL, and as was mentioned above, further case-
control studies on large groups are necessary.
The different softwares designed to predict potential TFBS
provide results which have to be evaluated in functional stud-
ies. Therefore, to resolve all arisen discrepancies, further in
silico, genetic and functional studies are needed.
As described above, we observed that heterozygosity at
rs9514828 and rs1041569 loci of the BAFF gene may protect
from CLL development. Therefore, we checked if rs9514828
CT and rs1041569 AT heterozygotes would have a better
prognosis in terms of overall survival, time to treatment, or
the requirement for introducing treatment. Neither rs9514828
CT nor rs1041569 AT heterozygotes had longer overall sur-
vival in comparison to both types of homozygotes. There was
also no association between the requirement for treatment and
heterozygosity at rs9514828 or at rs1041569. No association
was found between time to treatment and heterozygosity at
rs1041569. However, we observed that the average time to
beginning of treatment was much longer for rs1041569 AT
heterozygotes in relation to homozygotes AA and TT. This
result is in agreement with the lower risk of CLL for
rs1041569 AT heterozygotes, observed here. We are not able
to provide an explanation of this observation at this moment,
but the influence from interactions between TFs and adminis-
tered drugs cannot be excluded.
It has to be mentioned that we possessed a limited number
of samples with TTT data available. It will be interesting to
test our hypothesis of a protective role of heterozygosity at
rs9514828 and rs1041569 variants of the BAFF gene on a
larger group of CLL patients and HC.
As all BAFF SNPs analyzed in this study are located in
potential TFBS and the relationship between rs9514828
polymorphism and expression level of BAFF was shown
in luciferase assays [9, 22] and with serum BAFF levels
(sBAFF) [9], we also addressed these issues in our re-
search. We did not find any of the SNPs of the BAFF
promoter investigated in the present study to be associat-
ed with plasma BAFF levels or with intracellular expres-
sion of BAFF protein in PB CD19+ cells. Similarly,
Ansell et al. [37] did not find any significant association
between rs9514828 and sBAFF levels in follicular grade
1 non-Hodgkin lymphoma [37]. The same result was ob-
tained for pSS [16]. We examined the same SNPs of the
BAFF promoter region (rs9514827, rs3759467,
rs1041569, rs9514828) as had been previously studied
by Eilertsen [38] and Fabris [39] and colleagues, who
had investigated these SNPs in the systemic lupus erythe-
matosus and rheumatoid arthritis, respectively. These au-
thors also failed to find a relationship between serum
BAFF levels and investigated promoter variants of the
BAFF gene [38, 39]. Previously, Novak et al. [9] found
that sBAFF levels were higher in patients with familial
CLL than with sporadic CLL and suggested the correla-
tion between elevated levels of serum BAFF and the pres-
ence of a T at rs9514828 in the BAFF promoter [9]. Since
our cohort probably did not contain familial cases, we did
not observe such a correlation in our study.
In silico analysis as well as previously mentioned results
showing the association of rs9514828 with aberrant expres-
sion of BAFF gene suggested that we and other authors should
observe a correlation between at least this variant and the level
of BAFF. Due to the data available, we investigated only the
correlation between promoter variants and BAFF protein
levels. Any additional studies have to be designed to more
deeply examine the role of SNPs investigated here in the reg-
ulation of the BAFF gene.
BAFF-R is the main receptor for BAFF, and the BAFF/
BAFF-R pathway is crucial for the survival and growth of
CLL cells [5]. Hildebrand et al. [6] described an association
between the BAFF-R rs61756766 and the risk of non-
Hodgkin lymphoma such as the diffuse large B cell lympho-
ma, follicular lymphoma, lymphoplasmacytic lymphoma, and
mucosa-associated lymphoid tissue, but not with CLL. In the
same publication, they also reported a correlation between this
variant of the BAFF-R gene and the increased recruitment of
TRAF 2, 3, and 6 and showed that signaling through this
variant of BAFF-R resulted in increased NF-κB1 and
NF-κB2 activity [6]. In our study, we found that rs61756766
CT heterozygotes had two times higher risk of CLL than CC
homozygotes. Of note, we genotyped altogether 916 subjects
(patients and controls) and did not find any rs61756766 TT
homozygote. The frequency of the T allele was 2.7 % in pa-
tients and 1.4 % in HC. The absence of TT homozygotes was
expected, since the probability that there will be no TT homo-
zygotes within 439 cases and 477 controls given the above-
mentioned T allele frequencies is p = 0.6592. Due to such low
frequency of patients carrying the CT genotype for whom
complete clinical data were available, we were not able to
investigate potential relations between the presence of this
allele and clinical features. Apart from rs61756766, we geno-
typed three additional SNPs of the BAFF-R gene: rs6002551,
rs5996088, and rs7290134 [14]. We did not find any of these
SNPs to be associated with the risk of CLL, but we observed a
significant difference in haplotype distribution (formed by
four SNPs of BAFF-R) between CLL and HC patients, which
confirms that genetic predisposition to CLLmay be associated
with the BAFF-R gene.
In conclusion, in this study we investigated genetic varia-
tions in BAFF and BAFF-R in CLL including the assessment
of haplotypes, gene × gene interaction, and correlation with
clinical features. Our case-control study indicates a possible
association of the most widely studied rs9514828 SNP of the
BAFF gene as well as, described here for the first time, the
possible association of rs1041569 of the BAFF gene with the
risk of CLL.Moreover, this is the first study which showed the
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association between the BAFF-R gene rs61756766 and CLL
risk. Taking into consideration the fact that genetic predispo-
sition to CLL is still not well established, our results may help
to further investigate this issue and may ultimately help to
establish which of the genetic variations reported in the liter-
ature are the true CLL risk factors.
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